Loading...
XKRX
206650
Market cap328mUSD
Jun 16, Last price  
12,390.00KRW
1D
-0.64%
1Q
5.90%
IPO
190.50%
Name

EuBiologics Co Ltd

Chart & Performance

D1W1MN
XKRX:206650 chart
P/E
23.78
P/S
4.70
EPS
521.11
Div Yield, %
—
Shrs. gr., 5y
6.09%
Rev. gr., 5y
23.76%
Revenues
96.04b
+38.45%
1,602,679,0914,844,900,24011,567,747,40324,891,999,06233,072,579,69928,489,676,01239,384,938,14755,466,694,23669,365,660,61096,035,297,830
Net income
18.99b
P
-2,828,023,339-6,702,365,737-4,715,309,4353,780,519,903-881,624,055-60,134,488,690-27,574,028,750-1,098,855,365-13,878,968,42018,991,722,460
CFO
43.21b
+63.36%
-3,394,978,841-3,694,345,897-2,640,240,9792,936,794,20412,878,282,894-913,537,169-7,601,892,5706,440,151,98526,451,775,86043,211,897,730

Profile

EuBiologics Co., Ltd., a biopharmaceutical company, develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine. The company also provides customized services for mammalian cell and microbial cell derived biopharmaceuticals in accordance with the clients' project stages, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. It specializes in manufacturing a range of mammalian cell and microbial cell derived biopharmaceuticals, including recombinant biological products and antibody therapeutics. In addition, the company offers process, formulation, and analytical method development, as well as licensing consulting services; and contract testing services that include lot release, stability, raw material, and method validation testing services. The company was founded in 2010 and is based in Seoul, South Korea.
URL
http://www.eubiologics.com/
IPO date
Jan 24, 2017
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
96,035,298
38.45%
69,365,661
25.06%
55,466,694
40.83%
Cost of revenue
56,485,936
56,718,653
51,588,918
Unusual Expense (Income)
NOPBT
39,549,362
12,647,008
3,877,776
NOPBT Margin
41.18%
18.23%
6.99%
Operating Taxes
(534,513)
745,036
99,244
Tax Rate
5.89%
2.56%
NOPAT
40,083,875
11,901,972
3,778,532
Net income
18,991,722
-236.84%
(13,878,968)
1,163.04%
(1,098,855)
-96.01%
Dividends
Dividend yield
Proceeds from repurchase of equity
489,787
61,859
1,093,356
BB yield
-0.11%
-0.01%
-0.34%
Debt
Debt current
9,378,595
10,432,893
9,933,268
Long-term debt
8,022,277
6,868,169
5,729,375
Deferred revenue
11,669,241
11,879,268
9,278,655
Other long-term liabilities
11,767,113
25,592,020
5,127,854
Net debt
(21,044,612)
(9,600,496)
(13,143,635)
Cash flow
Cash from operating activities
43,211,898
26,451,776
6,440,152
CAPEX
(5,838,898)
(6,936,417)
(30,872,443)
Cash from investing activities
(26,997,682)
(28,109,753)
(2,132,461)
Cash from financing activities
(3,811,180)
566,029
634,580
FCF
36,701,275
32,257,883
(18,016,040)
Balance
Cash
37,946,320
11,491,379
11,054,022
Long term investments
499,163
15,410,179
17,752,256
Excess cash
33,643,719
23,433,275
26,032,943
Stockholders' equity
(97,718,580)
(118,285,258)
(101,423,761)
Invested Capital
266,137,881
240,544,178
247,110,855
ROIC
15.82%
4.88%
1.54%
ROCE
23.48%
9.28%
2.44%
EV
Common stock shares outstanding
36,617
36,448
36,402
Price
12,150.00
5.93%
11,470.00
28.88%
8,900.00
-74.61%
Market cap
444,899,004
6.42%
418,054,614
29.04%
323,976,937
-73.93%
EV
423,854,393
401,898,814
305,758,691
EBITDA
49,625,682
21,814,953
11,759,875
EV/EBITDA
8.54
18.42
26.00
Interest
1,138,532
1,054,860
508,289
Interest/NOPBT
2.88%
8.34%
13.11%